189 results
8-K
EX-99.1
MBRX
Moleculin Biotech Inc
9 May 24
Moleculin Announces U.S. Patent Issue Notification for Lipid-Based Delivery Technology for Annamycin
8:30am
, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties
8-K
EX-99.1
MBRX
Moleculin Biotech Inc
7 May 24
Moleculin Reports Higher AML Complete Remission (CR) Rates and Significant Durability with Additional Interim Subject Data
8:55am
the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act
8-K
EX-99.1
MBRX
Moleculin Biotech Inc
2 May 24
Regulation FD Disclosure
9:00am
27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which
8-K
EX-99.1
MBRX
Moleculin Biotech Inc
18 Apr 24
Regulation FD Disclosure
8:30am
of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act
8-K
EX-99.1
kwj0wc69ym45pfl2
10 Apr 24
Moleculin Announces Presentation of Positive Data Demonstrating High Anti-Cancer Activity of Annamycin and Non-Cardiotoxic Properties
8:30am
8-K
EX-99.1
ir8fb856vrhcvwigq
27 Mar 24
Moleculin Announces U.S. Patent Issue Notification for Annamycin Targeting Unmet Need in AML
9:05am
8-K
EX-99.1
qhfidqx5hkm6d6b54yc
25 Mar 24
Moleculin Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML Trial
7:30am
8-K
EX-99.1
ln8vdr938gph7xox7h
22 Mar 24
Moleculin Reports Full Year 2023 Financial Results
4:08pm
8-K
EX-99.1
fooogverp4t7x
19 Mar 24
Moleculin Announces Reverse Stock Split
4:31pm
424B3
zgjzgyfqopkbw
16 Feb 24
Prospectus supplement
5:19pm
8-K
EX-99.1
hge orkphc26mq9a75w
24 Jan 24
Regulation FD Disclosure
8:50am
8-K
EX-10.1
kp8r546m1has qxs
21 Dec 23
Moleculin Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market
5:17pm
8-K
EX-99.1
5yis c7fg8v6zjj
21 Dec 23
Moleculin Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market
5:17pm
8-K
EX-99.1
f8fh3f5t3 dj9ek
11 Dec 23
Moleculin Presents Positive Interim Data from Phase 1B/2 Clinical Trial in AML at Meeting with KOL’s in Conjunction with ASH Annual Meeting
8:50am
8-K
EX-99.1
se53ph qny9ps8be
13 Nov 23
Regulation FD Disclosure
8:05am
8-K
EX-99.1
38zc9tb 2o
13 Nov 23
Moleculin Reports Third Quarter 2023 Financial Results
8:00am
8-K
EX-99.1
w279csqeqnp w1m3ph
6 Nov 23
Regulation FD Disclosure
8:35am